Highlights
- •Patients with poor outcome at 3 months (mRS score > 2) had lower plasma GDF-8 levels at admission.
- •Lower GDF-8 levels were independently associated with poorer outcome at 3, 6 and 12 months.
- •GDF-8 could act as an early biomarker of functional recovery after ischemic stroke.
Abstract
Background
Identifying biological markers of ischemic stroke (IS) is an important research approach
to develop innovative therapeutic strategies. This study aimed to assess the association
between plasma Growth Differentiation Factor-8 (GDF-8)/Myostatin levels and outcome
of IS patients.
Methods
Consecutive patients with acute IS treated with either intravenous thrombolysis and/or
mechanical thrombectomy at Dijon University Hospital, France were prospectively included.
Clinical variables were recorded, and plasma GDF-8 was collected just after the revascularization
procedure. Primary endpoint was functional outcome at 3 months assessed by the modified
Rankin Scale (mRS) score. Secondary endpoints included mRS scores at 6 and 12 months,
and overall mortality over 1-year of follow-up.
Results
Among the 173 included patients (median age: 76 years, Interquartile range (IQR):
66–85; 49% women), median plasma GDF-8 levels at admission were significantly lower
in those with a poor outcome at 3 months defined as a mRS score > 2 (2073 (IQR: 1564-2757)
pg/mL versus 1471 (1192-2241) pg/mL, p < 0.001). Lower GDF-8 levels at admission were associated with higher 3-months mRS
score in multivariable ordinal logistic regression analysis (OR = 0.9995; 95% CI:
0.9991–0.9999, p = 0.011). The association was also observed with 6- and 12-month mRS scores. Although
mortality was higher in patients with lower GDF-8 levels, the association was not
significant in multivariable Cox analysis.
Conclusion
Lower plasma GDF-8 levels were associated with a poorer functional outcome in IS patients
treated with acute revascularization therapy. Underlying pathophysiological mechanisms
involving GDF-8 in post-stroke outcome remain to be elucidated.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016.Lancet Neurol. 2019; 18: 439-458https://doi.org/10.1016/S1474-4422(19)30034-1
- Epidemiology of stroke in Europe and trends for the 21st century.Presse Med. 2016; 45: e391-e398https://doi.org/10.1016/j.lpm.2016.10.003
- Impact of the ageing population on the burden of stroke: the Dijon stroke registry.Neuroepidemiology. 2019; 52: 78-85https://doi.org/10.1159/000492820
- The transforming growth factor-beta family.Annu. Rev. Cell Biol. 1990; 6: 597-641https://doi.org/10.1146/annurev.cb.06.110190.003121
- Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.Nature. 1997; 387: 83-90https://doi.org/10.1038/387083a0
- Myostatin expression in the adult rat central nervous system.J. Chem. Neuroanat. 2018; 94: 125-138https://doi.org/10.1016/j.jchemneu.2018.10.001
- Differential effects of myostatin deficiency on motor and sensory axons.Muscle Nerve. 2017; 56: E100-E107https://doi.org/10.1002/mus.25570
- Axon and muscle spindle hyperplasia in the myostatin null mouse.J. Anat. 2011; 218: 173-184https://doi.org/10.1111/j.1469-7580.2010.01327.x
- Myostatin-like proteins regulate synaptic function and neuronal morphology.Development. 2017; 144: 2445-2455https://doi.org/10.1242/dev.152975"22
- Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.Hum. Mol. Genet. 2009; 18: 997-1005https://doi.org/10.1093/hmg/ddn426
- Molecular mechanisms of skeletal muscle atrophy in a mouse model of cerebral ischemia.Stroke. 2015; 46: 1673-1680https://doi.org/10.1161/STROKEAHA.114.008574
- Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke.Sci. Rep. 2017; 7: 14000https://doi.org/10.1038/s41598-017-13912-0
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment.Stroke. 1993; 24: 35-41https://doi.org/10.1161/01.str.24.1.35
- Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay.Skelet. Muscle. 2015; 5: 21https://doi.org/10.1186/s13395-015-0047-5
- Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study.J. Clin. Endocrinol. Metab. 2012; 97: 3700-3708https://doi.org/10.1210/jc.2012-1273
- Quantification of GDF11 and Myostatin in human aging and cardiovascular disease.Cell Metab. 2016; 23: 1207-1215https://doi.org/10.1016/j.cmet.2016.05.023
- Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the heart and soul and HUNT3 cohorts.Eur. Heart J. 2015; 36: 3426-3434https://doi.org/10.1093/eurheartj/ehv385
- Growth differentiation Factor-8 (GDF8)/Myostatin is a predictor of troponin I peak and a marker of clinical severity after acute myocardial infarction.J. Clin. Med. 2019; 9: 116https://doi.org/10.3390/jcm9010116
- Stroke recurrence and prognosis after stroke.Handb. Clin. Neurol. 2009; 92: 407-421https://doi.org/10.1016/S0072-9752(08)01921-0
- Stroke history is an independent risk factor for poor prognosis in ischemic stroke patients: results from a large Nationwide stroke registry.Curr. Neurovasc. Res. 2020; 17: 487-494https://doi.org/10.2174/1567202617666200817141837
- Analysis of the risk factors for the short-term prognosis of acute ischemic stroke.Int. J. Clin. Exp. Med. 2015; 8: 21915-21924
- Diabetes worsens the outcome of acute ischemic stroke.Diabetes Res. Clin. Pract. 2005; 69: 293-298https://doi.org/10.1016/j.diabres.2005.02.001
- Predicting 90-day outcome after Thrombectomy: baseline-adjusted 24-hour NIHSS is more powerful than NIHSS score change.Stroke. 2021; 52: 2547-2553https://doi.org/10.1161/STROKEAHA.120.032487
- Predictive value of serum myostatin for the severity and clinical outcome of heart failure.Eur. J. Intern. Med. 2019; 64: 33-40https://doi.org/10.1016/j.ejim.2019.04.017"23
- Association between serum Myostatin levels, hospital mortality, and muscle mass and strength following ST-elevation myocardial infarction.Heart Lung Circ. 2022; 31: 365-371https://doi.org/10.1016/j.hlc.2021.08.018
- Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation.J. Biol. Chem. 2000; 275: 40235-40243https://doi.org/10.1074/jbc.M004356200
- Sarcopenia: revised European consensus on definition and diagnosis.Age Ageing. 2019; 48: 16-31https://doi.org/10.1093/ageing/afy169
- Association of serum adiponectin and myostatin levels with skeletal muscle in patients with obesity: a cross-sectional study.PLoS One. 2021; 16e0245678https://doi.org/10.1371/journal.pone.0245678
- Endocranial and masticatory muscle volumes in myostatin-deficient mice.R. Soc. Open Sci. 2014; 1140187https://doi.org/10.1098/rsos.140187
- Bone morphogenetic proteins promote neurite outgrowth in retinal ganglion cells.Mol. Vis. 2005; 11: 208-215
- Expression of myostatin in neural cells of the olfactory system.Mol. Neurobiol. 2013; 47: 1-8https://doi.org/10.1007/s12035-012-8342-1
- Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of spinal muscular atrophy.Neuromuscul. Disord. 2012; 22: 277-285https://doi.org/10.1016/j.nmd.2011.10.012
- Myostatin is associated with cognitive decline in an animal model of Alzheimer’s disease.Mol. Neurobiol. 2019; 56: 1984-1991https://doi.org/10.1007/s12035-018-1201-y
- Biochemistry and biology of GDF11 and Myostatin: similarities, differences, and questions for future investigation.Circ. Res. 2016; 118: 1125-1142https://doi.org/10.1161/CIRCRESAHA.116.308391
- Modulation of GDF11 expression and synaptic plasticity by age and training.Oncotarget. 2017; 8: 57991-58002https://doi.org/10.18632/oncotarget.19854
- Growth differentiation factor 11 treatment leads to neuronal and vascular improvements in the hippocampus of aged mice.Sci. Rep. 2018; 8: 17293https://doi.org/10.1038/s41598-018-35716-6
- Neuroprotective potential of GDF11: myth or reality?.Int. J. Mol. Sci. 2019; 20: 3563https://doi.org/10.3390/ijms20143563
- Growth differentiation factor 11 promotes neurovascular recovery after stroke in mice.Front. Cell. Neurosci. 2018; 12: 205https://doi.org/10.3389/fncel.2018.00205
- Growth differentiation factor 11 improves neurobehavioral recovery and stimulates angiogenesis in rats subjected to cerebral ischemia/reperfusion.Brain Res. Bull. 2018; 139: 38-47https://doi.org/10.1016/j.brainresbull.2018.02.011
- The neuroprotective and neurorestorative effects of growth differentiation factor 11 in cerebral ischemic injury.Brain Res. 2020; 1737146802https://doi.org/10.1016/j.brainres.2020.146802
Article info
Publication history
Published online: March 16, 2023
Accepted:
March 2,
2023
Received in revised form:
March 1,
2023
Received:
October 28,
2022
Identification
Copyright
© 2023 Published by Elsevier B.V.
